ARD-AB01

ARD-AB01 (also known as H2) is a bispecific antibody currently under development by Artivila Therapeutics for the treatment of solid tumors. As a bispecific antibody, it is engineered to simultaneously bind to two distinct antigens or epitopes, a strategy typically employed to enhance tumor selectivity, block multiple signaling pathways, or recruit immune effector cells to the tumor microenvironment. While the specific molecular targets and detailed mechanism of action have not been publicly disclosed by the developer, the candidate represents the only antibody-based modality in Artivila's primarily small-molecule-focused pipeline.